Atalanta Raises $97m To Advance RNAi Therapies For Epilepsy And Huntington’s
The company believes its divalent small interfering RNA technology can boost CNS penetration and durability and aims to have its first two programs in the clinic by 2026.
The company believes its divalent small interfering RNA technology can boost CNS penetration and durability and aims to have its first two programs in the clinic by 2026.